Plain-English translation of NCT05866432 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called datopotamab-deruxtecan to see if it can help people with advanced triple-negative breast cancer whose cancer has spread to the brain. The medication is given as an infusion through the vein once every three weeks. Researchers want to understand how well this treatment works for patients whose brain metastases are newly diagnosed or have started growing again after previous treatment.
Triple-negative breast cancer that spreads to the brain is particularly difficult to treat because available options are limited. This medication is designed to specifically target cancer cells and may be able to reach the brain more effectively than some other treatments, which is why researchers want to test whether it can help patients in this situation.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive infusions of the medication through a vein once every three weeks. Your doctors will monitor you with regular blood tests and brain imaging scans to see how well the treatment is working and to watch for any side effects. The study involves about 20 patients total, and you would be followed to see how your cancer responds to this new treatment approach.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Austria
Phase
Testing effectiveness
Sponsor
Medical University of Vienna
Collaborators
Daiichi Sankyo
Enrollment target
~20 participants
Started
July 2023
Primary completion
May 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 100 Years
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Rupert Rupert, MD
Medical University Vienna
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.